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This study describes a patient who developed radioactive iodine (RAI)-induced Graves’ 
disease (GD) with orbitopathy following total thyroidectomy for papillary thyroid 
microcarcinoma. The patient was a 49-year-old woman, who underwent total thyroidectomy 
for a nodular goitre, which was postoperatively diagnosed as papillary thyroid 
microcarcinoma. Following administration of low-activity RAI for performance of a 
diagnostic whole-body scan (WBS), she developed a clinically significant orbitopathy related 
to GD. Graves’ disease has been reported in patients receiving therapeutic RAI, but it is 
considered rare and usually presents as post-RAI immunogenic hyperthyroidism [1]. To our 
knowledge, this is the first report of RAI-induced GD manifesting as orbitopathy in a patient 
with thyroid remnants after administration of low-activity RAI. 
 
A 49-year-old female patient with a history of non-toxic nodular goitre was diagnosed with 
papillary thyroid microcarcinoma and underwent total thyroidectomy at a regional hospital. 
Pathologic examination showed a single focus of papillary thyroid cancer (PTC) 0.15 cm in 
diameter, with no metastatic lymph nodes or histological features of tumour aggressiveness. 
For postoperative examination, the patient was admitted to the Endocrinology Clinic of 
Holycross Cancer Centre (HCC). The patient showed no ocular symptoms, and ultrasound 
examination of the neck revealed no focal lesions in the thyroid bed. Immunoassays showed 
that this patient had normal concentrations of antibodies against thyroid-stimulating hormone 
(TSH) receptor (TRAb; 0.444 IU/L; reference range, 0–1.5 IU/L) and thyroglobulin (86.91 
IU/mL; reference range, 0–115 IU/mL), and abnormally high concentrations of anti-thyroid 
peroxidase antibodies (TPOAb; 108.60 IU/mL; reference range, 0–34 IU/mL). A diagnostic 
WBS was performed after stimulation with recombinant human TSH and administration of 
185 MBq of RAI. Uptake of marker was negligible on the left side of the thyroid bed, with an 
iodine uptake during the 24th hour of 0.3%, and with WBS showing no abnormal uptake 
outside the thyroid bed (Fig. 1). Three months after RAI WBS, the patient developed 
clinically significant orbitopathy. Assay by a local laboratory showed that her TRAb level 
was elevated (40 IU/L; reference range, 0–1 IU/L). Repeated laboratory tests showed similar 
results, and the patient was administered oral methylprednisolone therapy by a regional 
endocrinologist. Subsequently, the patient was admitted to HCC for follow-up of PTC. 
Physical examination showed an orbitopathy with a clinical activity score (CAS) of 2/7. 
TRAb remained elevated at 17.13 IU/L (reference range, 0–1.5 IU/l). Magnetic resonance 
imaging showed radiographic features typical of Graves’ orbitopathy (GO) (Fig. 2). One 
month later, her TRAb concentration remained elevated (20.61 IU/L) with orbitopathy having 
a CAS of 2/7. However, there was slight subjective clinical improvement. 
Methylprednisolone therapy was continued while tapering doses. Follow-up four months later 
showed decreases in TRAb (12.63 IU/L) and orbitopathy (CAS 1/7), as well as clinical 
improvements. Her methylprednisolone dose was lowered, with the intention of withdrawal. 
Three months later, at the most recent follow-up visit in December 2019, the patient showed 
no evidence of ocular symptoms or signs, although her TRAb level remained elevated (14.50 
IU/L). Methylprednisolone therapy was stopped.  
 Several pathophysiological mechanisms are thought to be responsible for the development of 
a very rare phenomenon, autoimmune hyperthyroidism, after RAI therapy for autonomous 
thyroid disease. Radiation damage to the thyrocytes results in the release of thyroid antigens 
and the activation of autoimmune reactions, inducing TRAb overexpression and GD. Graves’ 
orbitopathy is caused by the cross-reaction of those antibodies with tissue components in the 
orbit. In one study, only 15 (1.1%) of 1357 patients with autonomous thyroid disease 
developed post-RAI immunogenic hyperthyroidism between 1 and 13 months after RAI 
therapy, but only one of those 15 patients presented with endocrine orbitopathy [1]. Patients 
with elevated TPOAb before RAI therapy were found to be at 10-fold higher risk of 
developing post-radioiodine GD than patients with normal TPOAb levels. Although GD after 
previous RAI therapy is rare, it is related to higher RAI activities, averaging 370-555 MBq, 
and to preservation of the thyroid gland [3, 4]. Overt hyperthyroidism may be induced after 
total thyroidectomy by thyroid hormones produced by metastatic lesions of follicular thyroid 
cancer (FTC), but positive TRAb and GD is rarely triggered by repeated high activity RAI 
therapy in patients with metastatic FTC after total thyroidectomy [5]. The characteristics of 
our patient were unusual: a thyroid remnant after surgery, no metastases of thyroid cancer, 
administration of low-activity RAI, and RAI-induced GD manifesting clinically as GO and 
abnormally high TRAb.  
In summary, the results in this patient indicate that GD/GO may be induced by RAI 
administration following thyroid gland removal, particularly in TPO-positive patients.  
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Figure 1. Diagnostic thyroid bed scanning and whole-body scanning following administration 
of low-activity radioiodine. A. Diagnostic whole-body radioiodine scanning, showing 
negligible uptake of iodine in the thyroid bed and no abnormal uptake outside the thyroid bed. 
B. Thyroid bed scan, showing uptake of 0.3% radioiodine during the 24th hour 
 
 
  
 
Figure 2. Magnetic resonance imaging of the patient’s orbits. Magnetic resonance imaging 
showing stage I of radiological protrusion and enlargement of the eyelids and the extraocular 
muscles, including the inferior rectus and medial rectus muscles 
 
 
 
